Physician profile
Ryan M Gil
NPI 1235635368
$497.27
in general payments reported to CMS, 2019-2025
10 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $268 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $146.11 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Intuitive Surgical, INC. | $83.54 | 2024 | |
| Glaxosmithkline, LLC. | $81.78 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $57.14 | 2025 | Dupixent |
| Baxter Healthcare | $24.93 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.89 | 2025 | Fasenra |
| Jazz Pharmaceuticals INC. | $22.10 | 2025 | |
| Mylan Specialty L.P. | $19.42 | 2024 | Yupelri |
| Amgen INC. | $19.18 | 2024 | Tezspire |
| Axsome Therapeutics, INC. | $18.18 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.